Non-Hodgkin Lymphoma

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor of medicine (hematology and oncology), Northwestern University Feinberg School of Medicine, discussed emerging chemotherapy-free regimens in the treatment of patients with follicular lymphoma.

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

The FDA has granted a priority review designation to a supplemental new drug application for the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted umbralisib (TGR-1202) a breakthrough therapy designation for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.